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ABSTRACT: Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer
that constitutes positive transcription elongation factor b, is a well-validated target for
treatment of several diseases, including cancer and cardiac hypertrophy. In order to
aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the
CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-
(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T
and CDK2/cyclin A. We find that for a given CDK, the melting temperature of a
CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that
differential scanning fluorimetry (DSF) is a useful orthogonal measure of inhibitory
activity for this series. We have used DSF to demonstrate that the binding of these
compounds is independent of the presence or absence of the C-terminal tail region of
CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimida-
zone-1-β-D-ribofuranoside (DRB). Finally, on the basis of 11 cocrystal structures
bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-
(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather
than from the formation of specific polar contacts.
■ INTRODUCTION
Positive transcription elongation factor b (P-TEFb), a key
regulator of transcription in eukaryotic cells, has been identified
as a drug target for several pathologies including cardiac
hypertrophy and certain cancers.1 The P-TEFb complex is
composed of cyclin dependent kinase 9 (CDK9) associated
with cyclin T1 or T2.2 Several CDK9 inhibitory chemotypes
have been identified in the course of drug discovery targeting
cell-cycle regulatory CDK-cyclin complexes. These CDK
inhibitors have been found to induce apoptosis in cancer cells
through inhibition of P-TEFb, thereby reducing levels of RNA
transcripts that promote cell growth and cell survival.3−7
Several CDK9 inhibitors, including flavopiridol, N-[5-[[[5-(1,1-
dimethylethyl)-2-oxa(zolyl]methyl]thio]-2-thiazolyl]-4-
piperidinecarbox)amide (9, SNS-032; Chart 1),8 and 2-phenyl-
5,7-dihydroxy-8-(2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-
4H-chromen-4-ones (10, P276-00),9 are currently under
evaluation in clinical trials against cancer (http://clinicaltrials.
gov/). Although their cellular effects are consistent with
achieving inhibition of CDK9 at growth inhibitory concen-
trations, they demonstrate activity against a range of cyclin-
dependent kinases:1,9 flavopiridol inhibits CDK9 with a Ki of
3 nM but is a submicromolar inhibitor of CDK1 (Ki = 70 nM)
and CDK2 (Ki = 190 nM); 9 inhibits CDK9 with a Ki of 4 nM
but is also potent against CDK2 (Ki = 38 nM) and somewhat
active against CDK1 and CDK4 (Ki values of 480 and 925 nM,
respectively); 10 inhibits each of CDK1, CDK2, and CDK4,
with Ki values of less than 100 nM. While results obtained with
these inhibitors speak to the potential of CDK9 as a therapeutic
target, inhibitors that exhibit higher specificity for CDK9 are
needed to establish final target validation.
The P-TEFb complex is required for the synthesis of the
majority of RNA polymerase II (Pol II) transcripts.10 P-TEFb
promotes transcription elongation by phosphorylating the C-
terminal domain (CTD) of Pol II, as well as the pause inducing
factors NELF and DSIF.4,11 In addition to overcoming the
paused state of Pol II, these activities promote the further
processing of nascent transcripts. Inhibition of CDK9
selectively reduces the transcription of short-lived mRNAs,5
including those that encode regulators of proliferation and
apoptosis such as c-Myc and Mcl-1. These proteins are up-
Received: October 15, 2012
Published: December 20, 2012
Article
pubs.acs.org/jmc
© 2012 American Chemical Society 660 dx.doi.org/10.1021/jm301495v | J. Med. Chem. 2013, 56, 660−670
regulated in many cancers, leading to the inhibition of
apoptosis and the promotion of proliferation. The therapeutic
potential of interfering with these processes has been
highlighted by promising preclinical and clinical data gathered
for inhibitors of CDK9 and its regulators.12−16
The discovery of the 2,4-disubstituted pyrimidine CDK
inhibitors has been reported previously.17,18 Lead compounds
from this series induced apoptosis in cancer cells and exhibited
potent in vivo antitumor activity.19 This antitumor activity was
further shown to be due to inhibition of CDK9-dependent
transcription of antiapoptotic proteins.19−21 More recently, we
have identified a novel class of 2,4,5-trisubstituted pyrimidine
CDK inhibitors, as described in ref 22. 12c, one of the lead
compounds described in ref 22, induces apoptosis in cancer
cells more readily than in noncancerous cells and was able to
selectively kill patient-derived chronic lymphocytic leukemia
(CLL) cells.21 Taken together, these results support the view
that the N-phenyl-4-heteroarylpyrimidine-2-amine scaffold
might be optimized to yield a clinically useful CDK9 inhibitor.
In order to achieve this goal, we have conducted crystallo-
graphic studies to identify the inhibitor−target interactions that
promote CDK9-specific inhibition. As part of this investigation,
we have explored the behavior of analogues of 4-(thiazol-5-yl)-
2-(phenylamino)pyrimidine-5-carbonitrile in differential scan-
ning fluorimetry (DSF) experiments with P-TEFb and used
DSF experiments to explore whether the CDK9/cyclin T
affinity of such analogues is dependent on the presence of the
Chart 1
Table 1. Ki and ΔTm for 2-Amino-4-heteroarylpyrimidine and Other CDK9 Inhibitors
Ki (μM)
a ΔTm (°C)
compd R1 R2 R CDK9 CDK2 CDK9 CDK2
12a Me CN m-NO2 0.006 0.001 4.68 ± 0.29 8.88 ± 0.36
12c Me CN m-SO2NH2 0.006 0.004 4.12 ± 0.07 10.53 ± 0.18
12t Me CN m-acetylhomopiperazine 0.007 0.131 3.50 ± 0.30 2.77 ± 0.87
12u Me CN m-homopiperazine 0.007 0.568 3.92 ± 0.32 4.20 ± 0.87
1 Me CN p-SO2-morph 0.008 0.003 3.69 ± 0.05 NA
2 Me CN p-SO2NH2 0.008 0.0002 4.09 ± 0.65 NA
3 Me CN m-OH 0.011 0.012 4.12 ± 0.23 6.91 ± 0.90
4 Me CN m-SO2-morph, p-Me 0.022 0.123 3.00 ± 0.06 NA
5 Me CN p-OH 0.026 0.003 4.04 ± 0.09 NA
6 Me CN m-CO-morph 0.043 0.147 2.93 ± 0.08 1.96 ± 0.43
7 Ph H m-SO2-morph, p-Me 6.185 >5 0.154 ± 0.04 −0.61 ± 0.07
27a Ph H m-NO2 9.835 >5 −1.68 ± 0.21 −2.49 ± 0.36
staurosporine 0.007 0.004 3.60 ± 0.02 6.22 ± 0.08
flavopiridol 0.003 0.19 5.03 ± 0.13 NA
(S)-CR8b 0.110 0.08 3.29 ± 0.08 2.81 ± 0.73
8 0.340 65 1.22 ± 0.32 −1.37 ± 0.20
11 0.35 69 1.57 ± 0.10 0.152 ± 0.05
roscovitine 0.79 0.25 1.57 ± 0.02 2.56 ± 1.58
aApparent inhibition constants (Ki) were calculated from IC50 values and the appropriate Km (ATP) values for CDK9 and CDK2.
b(S)-CR8 is 2-(S)-
(1-ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurine.
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CDK9 tail region, as observed elsewhere for other CDK9-
selective inhibitors.23
Here and in ref 22, we present the crystal structures of six
analogues of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-car-
bonitrile bound to CDK9/cyclin T and CDK2/cyclin A and
analyze the similarities and differences in inhibitor binding to
these enzymes. Our analysis provides the most extensive
investigation of the CDK9 ATP binding site to date and allows
for a fuller interpretation of inhibitor binding to CDK9. The
data confirm that the ATP binding site of CDK9 presents a
highly malleable environment capable of accommodating a
range of chemically diverse moieties attached to the 4-(thiazol-
5-yl)-2-(phenylamino)pyrimidine scaffold.
■ RESULTS
Potent Inhibitors Thermally Stabilize CDK9/Cyclin T
and CDK2/Cyclin A. We used DSF to evaluate CDK9
inhibitors for their ability to bind to the enzyme. This
technique identifies the melting temperature (Tm) of a protein
and the change in melting temperature (ΔTm) induced by the
binding of inhibitors.24 The relatively high-throughput nature
of DSF allows rapid screening of both a large number of
inhibitors and analysis of different protein constructs.
All but two of the 4-(thiazol-5-yl)-2-(phenylamino)-
pyrimidines tested confer an increase in the thermal stability
of CDK9/cyclin T. The values measured ranged from 2.9 to 4.7
°C, indicating strong inhibitor binding (Table 1, Figure 1A,B,
and Supporting Information Figure S1). The two exceptions
were 7 and 27a. This result correlates with the observed Ki
values: strongly stabilizing inhibitors display Ki values in the
range 6−43 nM, while 7 and 27a have substantially lower
inhibitory activity against CDK9/cyclin T, with Ki values of
6.19 and 9.83 μM, respectively (Table 1). This correlation
between ΔTm and inhibitory Ki extends beyond the 4-(thiazol-
5-yl)-2-(phenylamino)pyrimidines (Figure 1A, Table 1).
Flavopiridol is the most potent CDK9 inhibitor studied here
(Ki = 3 nM) and gives rise to the largest increase in melting
temperature (ΔTm = 5.03 ± 0.13 °C). 8 (DRB)
25 is much less
potent than flavopiridol and stabilizes the complex by only 1.22
± 0.32 °C. Similar correlations between potency and effect on
Tm have been reported previously for inhibitors of other kinases
including the PIM-1 kinase and AAK1.24,26
To compare inhibitor binding to CDK9/cyclin T with
inhibitor binding to CDK2/cyclin A, we next evaluated the
ΔTm induced by the binding of these inhibitors to CDK2/
cyclin A. This DSF analysis shows that ΔTm and Ki also
correlate for inhibitor binding to CDK2/cyclin A (Figure 1B).
However, the ΔTm values induced by inhibitor binding to
CDK2/cyclin A are systematically higher than those induced by
inhibitor binding to CDK9/cyclin T. For this reason, the
absolute ΔTm values induced by a given inhibitor binding to the
two different CDK/cyclin complexes do not directly predict the
relative selectivity of that inhibitor.
Nevertheless, DSF provides a straightforward method to
identify compounds that are potent against one or more CDKs.
For example, compound 3 induces a thermal shift of >4 °C for
Figure 1. Stabilization of CDK9/cyclin T and CDK2/cyclin A by 2-amino-4-heteroarylpyrimidines. (A, B) ΔTm values for CDK9/cyclin T (A) or
CDK2/cyclin A (B) bound to a set of selected inhibitors are plotted against the corresponding IC50 values, showing a strong correlation between
ΔTm and IC50. A log−linear trend line for CDK2 has an R2 of 0.79, while the equivalent line for CDK9 has an R2 of 0.91. (C) ΔTm values induced by
inhibitor binding to CDK9/cyclin T (solid bars) and CDK2/cyclin A (open bars) are compared. DRB and CAN508 correspond to 8 and 11. (D)
ΔTm values induced by inhibitor binding to full length CDK9/cyclin T (solid bars) and CDK9330/cyclin T (open bars) are compared.
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CDK9/cyclin T and >6.5 °C for CDK2/cyclin A, reflecting its
activity as a potent inhibitor of both kinases (Table 1 and
Figure 1C). By contrast 12t increases the Tm of CDK9/cyclin T
by an amount greater than it does that of CDK2/cyclin A,
confirming the Ki data that identify this compound as being
CDK9 selective. However, the generally greater effect of
inhibitor binding on the Tm of CDK2 means that it is not
justified to infer CDK2 selectivity over CDK9 from a relatively
higher ΔTm: 12u, which stabilizes CDK2 more than it stabilizes
CDK9, turns out to be a more potent inhibitor of CDK9.
Potency of the 4-(Thiazol-5-yl)-2-(phenylamino)-
pyrimidines toward CDK9 Is Not Dependent on the
Presence of the CDK9 C-Terminal Tail. Previous studies
have shown that the C-terminus of CDK9 contributes to the
binding affinity of the CDK9-selective inhibitor 8.23 To
determine if the C-terminal tail influences the binding of the
4-(thiazol-5-yl)-2-(phenylamino)pyrimidines, we measured the
stabilization induced by these inhibitors on a CDK9/cyclin T
complex containing a version of CDK9 truncated at the C-
terminus (CDK9330/cyclin T) and compared the results to
those observed for the full-length CDK9/cyclin T complex
(Figure 1D). This comparative analysis showed that, in contrast
to 8, the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines show
little ability to discriminate between CDK9/cyclin T and
CDK9330/cyclin T. This result suggests that the C-terminal tail
neither forms nor significantly modulates interactions between
the CDK9 active site and this family of inhibitors.
4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbon-
itrile CDK Inhibitors Adopt the Same Binding Mode
within the ATP Binding Sites of CDK9 and CDK2. The
detailed structure−activity relationship (SAR) of this chemical
series has been discussed in ref 22. In brief, different functional
groups attached to the pyrimidinyl or aniline ring system have a
dramatic effect on CDK potency and selectivity. In order to
rationalize the observed SAR, we solved the crystal structures of
six representative inhibitors bound to both CDK9 and CDK2
(Table 2, Figure S2, and Table S1), described here and in ref
22.
The core of each of the inhibitors adopts a similar pose
within the active sites of CDK9/cyclin T and CDK2/cyclin A
(Figure 2). The thiazole, pyrimidine, and aniline moieties
occupy similar positions within the ATP binding sites, and each
of the inhibitors forms similar hydrogen bonds to the hinge
regions of each kinase (Figure 2, and as detailed in ref 22). The
pyrimidine ring is sandwiched between the hydrophobic side
chains of Ala46 (Ala31) (CDK9 (CDK2) numbering
throughout) and Leu156 (Leu134). At the back of the ATP
binding site, the C5-carbonitrile contacts the gatekeeper residue
Phe103 (Phe80), forming a lone pair−π interaction (mean
distance from the nitrile nitrogen to atoms of the phenyl ring is
3.7 Å).
In the majority of these structures the thiazole moiety has
less well-defined electron density bound to CDK9/cyclin T or
CDK2/cyclin A than do the other heterocyclic moieties of the
inhibitor, suggesting that it may adopt multiple alternative
conformations. In CDK9 the thiazole ring within the ATP-
binding site causes the side chain of Lys48 to become defined
by electron density, presumably by preferentially stabilizing a
unique conformation. By contrast, the equivalent residue in
apo-CDK9/cyclin T (PDB code 3BLH) is mobile and lacks
electron density. In the major CDK9/cyclin T-bound
conformation, the methylamino group substituted on the
thiazole hydrogen bonds with Asp167 (Figure 2). In CDK2/
cyclin A the electron density indicates two main conformations
for the thiazole moiety. The first resembles the conformation
adopted by the thiazole group when bound to CDK9/cyclin T
and is stabilized by the formation of favorable interactions
between the methylamino group and Asp145. The second
conformation is approximately coplanar with the pyrimidine
and hence stabilized by conjugation of the aromatic systems.
Toward the front of the ATP binding pocket, the aniline ring is
contacted from above by Ile25 (Ile11) with which it forms
favorable van der Waals interactions.
Within the CDK2/cyclin A and CDK9/cyclin T crystal
structures, meta-substituents of the aniline group are observed
in two distinct locations. The first has the substituents
positioned toward the thiazole ring, close to the location of
the ribose moiety of ATP in other kinase structures. We term
this the “inward” conformation. By contrast, the second
orientation corresponds to a rotation of 180° around the
nitrogen−phenyl bond so that the substituents are positioned
away from the thiazole and are therefore directed toward hinge
residues. We term this the “outward” conformation (Figure 2
and Supporting Information Figure S2).
4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbon-
itriles Form Few Polar Contacts with CDK9 and CDK2.
Analysis of the structures shows that there are few specific
hydrogen bonds or ionic interactions between the CDKs and
the substituents that decorate the 2-amino-4-heteroarylpyr-
imidine scaffold (Table 2). This is particularly apparent for the
CDK9/cyclin T complexes in which only the peptide carbonyl
of Glu107 hydrogen-bonds with the sulfonamide and hydroxyl
groups of 12c and 3, respectively (Figure 2C). In the CDK2/
cyclin A complexes, 3, 4, and both orientations of the
sulfonamide of 12c form polar interactions with CDK2. The
hydroxyl group of 3 hydrogen-bonds with Asp86. The SO2 of 4
forms interactions with a water molecule, the Lys89 side chain,
and the peptide bond of Asp86, and the sulfonamide of 12c is
positioned for favorable interaction with Asp86 in an inward
conformation or with Lys89 and His84 in the outward
conformation (Figure 2D).
Table 2. Polar Interactions Identified for the 2-Amino-4-
heteroarylpyrimidine Substituents within the CDK9 and
CDK2 Active Sites
polar interactions
inhibitor R CDK9 CDK2
12t m-acetylhomopiperazin
3 m-OH Glu107 water, Asp86
4 m-SO2-morph, p-Me water, Asp86, Lys89
6 m-CO-morph no data
12u m-homopiperazin
12c m-SO2NH2 Glu107 Asp86,
a Lys89,b His84b
aInteractions observed for 12c in the inward conformation.
bInteractions observed for 12c in the outward conformation.
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The homopiperazine moieties of 12u and 12t appear not to
form polar contacts with either CDK9 or CDK2 (Table 2). 12u
and 12t are both selective for CDK9/cyclin T over CDK2/
cyclin A, with 12t displaying ∼20-fold selectivity and 12u
displaying ∼80-fold selectivity. These selectivities arise without
apparent formation of any polar interactions and must therefore
be derived from other contacts between kinase and inhibitor.
We deduce that most of the CDK9/cyclin T specificity
demonstrated by this pair of inhibitors results from a capacity
of CDK9/cyclin T to bind to them in a way that optimizes
apolar intermolecular contacts, without introducing strain in
the inhibitor. This capacity may, in turn, be determined by the
malleability of the CDK9 ATP binding site, which allows it to
accommodate the inhibitors in their most favored conforma-
tions.
Larger Inhibitors Can Be Accommodated in the CDK9
ATP Binding Site. Consistent with the hypothesis that
relatively large inhibitors might selectively bind to CDK9
Figure 2. The binding mode for the 2-amino-4-heteroarylpyrimidine class of inhibitors is similar in the ATP-binding sites of CDK9/cyclin T and
CDK2/cyclin A. (A, B) A summary of the common interactions made by 2-amino-4-heteroarylpyrimidine inhibitors bound to CDK9/cyclin T (A)
or CDK2/cyclin A (B) is illustrated using structural formulas. (C, D) Superimposed backbone conformations for 2-amino-4-heteroarylpyrimidine
complexes of CDK9/cyclin T (green carbons, panel C) or CDK2/cyclin A (blue carbons, panel D) are illustrated in ribbon representation, with the
inhibitor (gray carbon atoms) and contacting amino acids shown in cylinder representation. Hydrogen bonds are shown as dotted lines. (E, F)
Binding of compound 6 to CDK2 in two different conformations, colored as for panel D, and with the corresponding refined 2mFo − DFc electron
density contoured at 1σ.
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because of the comparative malleability of its ATP binding site,
12t, 4, 6, and 12u, which all have a bulkier substituent on the
aniline ring, demonstrate appreciable selectivity for CDK9 over
CDK2 when compared to other analogues shown in Table 1.
Our crystal structures identify different conformations for the
respective m-homopiperazine and m-acetylhomopiperazine
groups of 12u and 12t when bound to CDK9/cyclin T and
CDK2/cyclin A (Figure 3). The m-acetylhomopiperazine and
m-homopiperazine moieties of 12u and 12t are both
accommodated by CDK9 in the inward conformation. This
preference differs from that observed for CDK2, where the
rings are either disordered or predominantly adopt an outward
conformation (Table 2). We propose that the inward
conformation observed in the CDK9/cyclin T complexes is
the preferred conformation for the inhibitors and that its
exclusion from the CDK2/cyclin A complexes explains, in part,
the selectivity of the inhibitors for CDK9/cyclin T over CDK2/
cyclin A.
The crystal structures of 4 and 6 show that both compounds
bind in an inward conformation to CDK2/cyclin A and that 4
adopts an inward conformation when bound to CDK9/cyclin T
(no data are available for 6 bound to CDK9/cyclin T). Both
inhibitors show a modest selectivity for CDK9/cyclin T over
CDK2/cyclin A (6.0-fold and 3.5-fold, respectively), consistent
with the hypothesis that selectivity is limited where both
CDK2/cyclin A and CDK9/cyclin T are able to accommodate
the inhibitor in an identical conformation. The additional
hydrogen bonds made by the sulfonamide moiety of 4 to Asp86
and Lys89 of CDK2 may help stabilize the compound in the
inward conformation and thereby mitigate other binding
penalties associated with this pose. Compounds 2 and 5
show excellent potency against CDK2 and significant selectivity
Figure 3. CDK9/cyclin T has a more flexible ATP-binding site than CDK2/cyclin A. (A, B) Compound 12u, as bound to CDK9/cyclin T (green
carbons, panel A) or CDK2/cyclin A (blue carbons, panel B), is shown in ball and stick representation, with carbons colored gray. Final refined 2mFo
− DFc electron density is shown in cyan, contoured at 1σ. (C, D) Corresponding illustration of the binding of compound 12t to CDK9/cyclin T (C)
or CDK2/cyclin A (D). Within CDK9/cyclin T, 12t and 12u interact in an inward conformation, whereas in the context of CDK2/cyclin A, 12t and
12u bind either partially (12t) or predominantly (12u) in an outward conformation.
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over CDK9. The introduction of polar groups, including
hydroxyl and sulfonamide, at the para position of equivalent
aryl groups in other series of CDK inhibitors has had similarly
dramatic effects on their potency and selectivity for CDK2.27
These effects have been ascribed to the formation of optimal
and concerted stacking and hydrogen-bonding interactions with
the main chain of residues beyond the hinge and with the side
chain of Asp86, respectively.
Inhibitor Binding Can Induce Subdomain Movements
in CDK9 and CDK2. Inhibitor binding to CDK9/cyclin T can
provoke unique tertiary structural changes around the ATP-
binding site.28,29 The inhibitors included in this study induce
similar structural changes in CDK9, confirming the enzyme’s
structural malleability. By contrast, the binding of most
inhibitors to CDK2/cyclin A results in no significant structural
changes within the active site.
There are two main differences observed between the apo-
and inhibitor-bound states of CDK9. First, the glycine-rich loop
folds down to enclose or shield the inhibitor from solvent
(Figure 4). Concurrently the β3/αC loop adopts an altered
conformation in which it partially occupies the site vacated by
the movement of the glycine-rich loop. In this conformation
Leu51 adopts the structural role played by Phe30 in the apo
structure. In both the 12u- and 12t-bound structures there is a
further slight movement of the glycine-rich loop so that it can
make an additional contact with Asp127 in the CDK9 C-
terminal lobe. Weak electron density and high B-factors
indicate that the glycine-rich loop has conformational flexibility
in its downward position. In comparison it remains in a more
open conformation in the majority of CDK2/cyclin A/inhibitor
structures.
Second, the N- and C-terminal lobes of CDK9 adopt
different relative orientations in the presence and absence of
inhibitor (Figure 4). This difference corresponds to a rotation
that is particularly apparent on inspection of the cyclin subunit
after superimposing CDK9 subunits on their C-terminal kinase
lobes. A similar reconfiguration has been reported previously in
the CDK9/cyclin T/HIV-Tat (PDB code 3MIA) structure and
in certain other CDK9/cyclin T/inhibitor structures.28,30
■ DISCUSSION
The strong correlation between ΔTm and IC50 values for 2-
amino-4-heteroarylpyrimidine inhibitors confirms that DSF
both cross-validates CDK9 inhibition assays and offers a
potential surrogate for IC50 determination in assessing inhibitor
binding. Analysis of the 4-(thiazol-5-yl)-2-(phenylamino)-
pyrimidine series by this technique confirms that they
predominantly stabilize CDK9/cyclin T in a manner
Figure 4. Inhibitor-induced conformational changes. (A) The protein conformations in novel CDK9/cyclin T/inhibitor structures (green ribbon
representation) are compared with the conformation of CDK9/cyclin T in the absence of inhibitor (PDB code 3BLQ, orange ribbon
representation). (B) The protein conformations in representative novel CDK2/cyclin A/inhibitor structures (blue ribbon representations) are
compared with that of CDK2/cyclin A in the absence of inhibitor (PDB code 1QMZ, yellow ribbon representation). (C) Detail of the
conformational change induced by the binding of 12u (cylinder representation) on CDK9/cyclin T (green ribbon representation), relative to
CDK9/cyclin T in the absence of inhibitor (PDB code 3BLQ, orange ribbon representation). (D) Detail of the conformational change induced by
the binding of 3 and 12t (cylinder representation) on CDK2/cyclin A (blue ribbon representation), relative to CDK2/cyclin A in the absence of
inhibitor (PDB code 1QMZ, yellow ribbon representation). Kinase complexes were superimposed on their kinase C-terminal lobes (i.e., CDK2
residues 101−286 and CDK9 residues 123−316).
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independent of the C-terminal tail. In addition, the data
confirm that inhibitors 12t, 3, and 6, are potent CDK9/cyclin T
inhibitors that demonstrate varying degrees of CDK isotype
specificity. Biophysical techniques such as DSF (e.g., ref 24)
and calorimetry31are playing an increasing role in drug
discovery, and this work provides a further example of how
such techniques can provide an orthogonal measure of
protein−ligand interactions.
Deregulation of the P-TEFb pathway has been identified in
several cancers,32 and a number of CDK9 inhibitors are in
clinical trials. 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-
carbonitriles down-regulate the antiapoptotic protein Mcl-1
and show selective cytotoxic activity against patient-derived
primary CLL cancer cells.22 We have determined that members
of this inhibitor class bind within the ATP-binding site and
stabilize CDK9/cyclin T, employing a number of interactions
that do not depend on the presence of the CDK9 tail sequence.
Furthermore we have shown that these inhibitors adopt a
conserved binding pose and that, within this series, different
aniline substituents bind in subtly different ways.
Bis-hetaryl scaffolds have shown up as privileged chemotypes
among CDK inhibitors (reviewed in ref 33), but the molecules
described here stand out for their CDK9 inhibition. The
compounds included in this study are potent CDK9 inhibitors
and show a range of potencies toward CDK2. Where they
display appreciable selectivity for CDK9, the major determinant
appears to be their ability to simultaneously make favorable
hinge region contacts and van der Waals contacts, as opposed
to selective electrostatic or hydrogen bonds. Within the series,
differences in specificity can be rationalized by considering the
identity and size of the aniline substituent. Bulky substituted
anilines can be accommodated within the ATP binding site of
CDK9, but when bound to CDK2, they often extend out of the
binding site into the solvent exposed channels. This binding
mode is unique to this set of compounds as other smaller
CDK9 inhibitors such as flavopiridol, 8, and 4-arylazo-3,5-
diamino-1H-pyrazole (11, CAN508)35 achieve potency by
probing alternative pockets within the ATP-binding site of
CDK9.28,29,36
Molecular dynamics simulations (e.g., ref 34) conducted on
CDKs and CDK/cyclin complex have illustrated that parts of
the ATP-binding site, and most notably the glycine-rich lid, are
highly dynamic in nature, presumably associated with a demand
for flexibility during the kinase catalytic cycle. The studies
presented here provide further, experimentally supported
insight into the nature of plastic deformations that the CDK
glycine-rich loop may undergo and identify a markedly higher
degree of plasticity in the CDK9 than the CDK2 structure.
This study is the largest to date to provide structural details
of the interactions of a series of inhibitors with CDK9/cyclin T
and a comparison of their binding to CDK2/cyclin A. Taken
together, these results suggest that the malleable CDK9 active
site, unlike that of CDK2, can accommodate large and flexible
compounds providing a structural explanation for the observed
selectivity of such compounds for CDK9/cyclin T over CDK2/
cyclin A. This property, which provides a rationale for the
impressive selectivity of 12u and 12t toward CDK9/cyclin T
over CDK2/cyclin A, will help to focus chemical synthesis in
future inhibitor development.
■ EXPERIMENTAL SECTION
Protein Preparation. CDK9/cyclin T (residues 1−259) (termed
CDK9/cyclin T) and CDK9 (residues 1−330)/cyclin T (residues 1−
259, Q77R, E96G, F241L) (termed CDK9330/cyclin T) were
expressed and purified as reported in refs 23 and 28, respectively.
Expression and purification of CDK2/cyclin A (residues 174−432)
were undertaken in a similar manner to that in ref 37.
Crystallization. CDK9330/cyclin T crystals were obtained at 4 °C
using 10−16% PEG 1000, 100 mM Na/K phosphate, pH 6.2, 500 mM
NaCl, and 4 mM tris(2-carboxyethyl)phosphine hydrochloride
(TCEP) as the precipitant solution. Crystals were soaked in the
precipitant solution containing 1 mM inhibitor before being buffer
exchanged into a cryoprotectant solution containing the precipitant
solution supplemented with 15% glycerol and 1 mM inhibitor. Crystals
were subsequently flash-cooled in liquid nitrogen.
For cocrystallization, CDK2/cyclin A was first concentrated to 11.9
mg/mL and then incubated in the presence of 0.2 mM inhibitors for
20 min on ice. The solution was filtered through a microfiltration unit
(Amicon Ultrafree-MC) and subsequently mixed in equal volumes
with mother liquor composed of 1−1.25 M ammonium sulfate, 0.5−
0.9 M KCl, 100 mM HEPES, pH 7.0, and 5 mM dithiothreitol (DTT).
Crystals were cryoprotected in 7 M sodium formate before flash
cooling in liquid nitrogen.
Data Collection and Processing. Data were collected at the
Diamond Light Source on beamlines I-02, I-03, I-04 or at the
European Synchrotron Radiation Facility on beamline ID14-EH4.
MOSFLM38 or XDS39 was used to index and integrate the data. Data
were scaled using SCALA.40 Initial models were produced by
molecular replacement using PHASER41 or rigid body refinement in
phenix.refine.42 Models were iteratively improved by alternate rounds
of refinement using either REFMAC43 or phenix.refine and rebuilding
in COOT.44 External restraints to apo-CDK9/cyclin T were identified
in PROSMART40 and applied to CDK9/cyclin T structures refined in
REFMAC. Inhibitor restraints were produced using phenix.elbow
builder and confirmed by visual inspection of the resulting PDB and cif
files.
Thermal Denaturation. An amount of 0.95 μg of protein was
incubated with 20 μM inhibitor, 5× SYPRO Orange (Molecular
Probes) in 20 mM HEPES, pH 7.0, 500 mM NaCl, 10% glycerol, 3
mM DTT. The total reaction volume was 15 μL. The temperature was
raised in 1 °C steps starting at 25 °C and terminating at 80 °C. The
fluorescence emitted at 570 nm was measured using a Stratagene
mx3005P RT-PCR 305 machine. The temperature dependence of the
fluorescence during the protein denaturation process was approxi-
mated by the equation
= +
−
+ Δ
y T y
y y
( )
1 e RTF
U F
uG /( )T( )
where ΔuG is the difference in unfolding free energy between the
folded and unfolded state, R is the gas constant, and yF and yU are the
fluorescence intensity of the probe in the presence of completely
folded and unfolded protein, respectively.45 The baselines of the
denatured and native state were approximated by a linear fit. The
observed temperature shifts, ΔTm, for each inhibitor were recorded as
the difference between the transition midpoints of sample and
reference wells within the same plate and determined by nonlinear
least-squares fit.
Chemistry. 1H NMR and 13C NMR spectra were obtained using a
Bruker 400 Ultrashield spectrometer at 400 and 100 MHz,
respectively. These were analyzed using the Bruker TOPSPIN 2.1
program. Chemical shifts are reported in parts per million relative to
an internal tetramethylsilane standard. Coupling constants (J) are
reported to the nearest 0.1 Hz. The following abbreviations are used: s,
singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. High
resolution mass spectra were obtained using a Waters 2795 single
quadrupole mass spectrometer/micromass LCT platform. Purity for
final compounds was greater than 95% and was measured using Waters
high performance liquid chromatograph (Waters 2487 dual wave-
length absorbance detector) with a Phenomenex Gemini-NX 5u C18
110A 250 mm × 4.60 mm column, UV detector at 254 nm, using
system A (10% MeOH containing 0.1% TFA for 4 min, followed by
linear gradient of 10−100% MeOH over 6 min at a flow rate of 1 mL/
min), system B (10% MeCN containing 0.1% TFA for 2 min, followed
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by linear gradient of 10−100% over 10 min at a flow rate of 1 mL/
min), and system C (10% MeCN containing 0.1% TFA for 4 min,
followed by linear gradient of 10−100% over 10 min at a flow rate of 1
mL/min). Melting points were determined with an Electrothermal
melting point apparatus.
Preparation of compounds 12a, 12c, 12t, 12u, and 27a has been
described in ref 22. The following compounds were prepared by the
same methods.
4- (4 -Methy l -2 - (methy lamino ) th iazo l -5 -y l ) -2 - ( (4 -
(morpholinosulfonyl)phenyl)amino)pyrimidine-5-carbonitrile
(1). 1 was obtained from 3-(dimethylamino)-2-(4-methyl-2-
(methylamino)thiazole-5-carbonyl)acrylonitri le and 1-(4-
(morpholinosulfonyl)phenyl)guanidine. Yellow solid (13% yield);
mp 250−251 °C. Anal. RP-HPLC: tR 12.37 min (method A), 12.00
(method B), purity 96%. 1H NMR (DMSO-d6): δ 2.46 (s, 3H, CH3),
2.86 (apparent t, 4H, J = 4.8 Hz, 2 × CH2), 2.91 (d, 3H, J = 4.8 Hz,
CH3), 3.64 (apparent t, 4H, J = 4.8 Hz, 2 × CH2), 7.71 (dt, 2H, J =
8.8, 2.0 Hz, 2 × Ph-H), 8.03 (dt, 2H, J = 8.8, 2.0 Hz, 2 × Ph-H), 8.32
(q, 1H, J = 4.8 Hz, NH), 8.88 (s, 1H, Py-H), 10.69 (s, 1H, NH). 13C
NMR (DMSO-d6): δ 20.09, 31.33, 46.39, 65.74, 95.30, 114.13, 117.96,
120.20, 127.96, 129.16, 144.12, 156.48, 159.13, 161.45, 164.21, 170.84.
HR-MS (ESI+): m/z [M + H]+ calcd for C20H22N7O3S2, 472.1226,
found, 472.1217.
4-((5-Cyano-4-(4-methyl-2-(methylamino)thiazol-5-yl)-
pyrimidin-2-yl)amino)benzenesulfonamide (2). 2 was obtained
from 3-(dimethylamino)-2-(4-methyl-2-(methylamino)thiazole-5-
carbonyl)acrylonitrile and 4-guanidinobenzenesulfonamide. Yellow
solid (67% yield); mp 254−255 °C. Anal. RP-HPLC: tR 11.40 min
(method A), 11.27 (method B), purity 98%. 1H NMR (DMSO-d6): δ
2.45 (s, 3H, CH3), 2.91 (d, 3H, J = 4.8 Hz, CH3), 7.71 (d, 2H, J = 8.8
Hz, 2 × Ph-H), 8.03 (d, 2H, J = 8.8 Hz, 2 × Ph-H), 8.31 (q, 1H, J =
4.4 Hz, NH), 8.86 (s, 1H, Py-H), 10.57 (s, 1H, NH). 13C NMR
(DMSO-d6): δ 20.11, 31.33, 94.98, 114.28, 118.04, 120.05, 126.94,
138.36, 142.55, 156.25, 159.17, 161.45, 164.16, 170.79. HR-MS
(ESI+): m/z [M + H]+ calcd for C16H16N7O2S2, 402.0807, found,
402.0809.
2-((3-Hydroxyphenyl)amino)-4-(4-methyl-2-(methylamino)-
thiazol-5-yl)pyrimidine-5-carbonitrile (3). 3 was obtained from 3-
(dimethylamino)-2-(4-methyl-2-(methylamino)thiazole-5-carbonyl)-
acrylonitrile and 1-(3-hydroxyphenyl)guanidine. Yellow solid (18%
yield); mp 242−243 °C. Anal. RP-HPLC: tR 11.75 min (method A),
11.50 (method B), purity 99%. 1H NMR (DMSO-d6): δ 2.43 (s, 3H,
CH3), 2.89 (d, 3H, J = 4.4 Hz, CH3), 6.44−6.51 (m, 1H, Ph-H), 7.10
(t, 1H, J = 8.0 Hz, Ph-H), 8.03 (d, 1H, J = 8.4 Hz, Ph-H), 7.22 (s, 1H,
Ph-H), 8.24 (q, 1H, J = 4.8 Hz, NH), 8.77 (s, 1H, Py-H), 9.39 (s, 1H,
OH), 10.11 (s, 1H, NH). 13C NMR (DMSO-d6): δ 19.92, 31.29,
93.93, 108.19, 110.88, 111.89, 118.31, 129.60, 140.36, 155.80, 157.99,
159.41, 161.46, 163.90, 170.57. HR-MS (ESI+): m/z [M + H]+ calcd
for C16H15N6OS, 339.1028, found, 339.1078.
4-(4-Methyl-2-(methylamino)thiazol-5-yl)-2-((4-methyl-3-
(morpholinosulfonyl)phenyl)amino)pyrimidine-5-carbonitrile
(4). 4 was obtained from 3-(dimethylamino)-2-(4-methyl-2-
(methylamino)thiazole-5-carbonyl)acrylonitrile and 1-(4-methyl-3-
(morpholinosulfonyl)phenyl)guanidine. Yellow solid (35% yield);
mp 244−246 °C. Anal. RP-HPLC: tR 12.35 min (method A), 12.15
(method B), purity 98%. 1H NMR (DMSO-d6): δ 2.43 (s, 3H, CH3),
2.53 (s, 3H, CH3), 2.89 (d, 3H, J = 4.4 Hz, CH3), 3.06 (apparent t,
4H, J = 4.8 Hz, CH2 × 2), 3.63 (apparent t, 4H, J = 4.8 Hz, CH2 × 2),
7.43 (d, 1H, J = 8.4 Hz, Ph-H), 7.95 (dd, 1H, J = 8.4, 2.0 Hz, Ph-H),
8.18 (d, 1H, J = 2.0 Hz, Ph-H), 8.28 (q, 1H, J = 4.8 Hz, NH), 8.82 (s,
1H, Py-H), 10.46 (bs, 1H, NH). 13C NMR (DMSO-d6): δ 19.96,
20.21, 31.36, 45.77, 66.04, 118.11, 121.45, 125.00, 131.82, 133.67,
135.28, 137.79, 159.26, 161.55, 164.12, 170.82. HR-MS (ESI+): m/z
[M + H]+ calcd for C21H24N7O3S2, 486.1383, found 486.1421.
2-((4-Hydroxyphenyl)amino)-4-(4-methyl-2-(methylamino)-
thiazol-5-yl)pyrimidine-5-carbonitrile (5). 5 was obtained from 3-
(dimethylamino)-2-(4-methyl-2-(methylamino)thiazole-5-carbonyl)-
acrylonitrile and 1-(4-hydroxyphenyl)guanidine. Yellow solid (18%
yield); mp 251−252 °C. Anal. RP-HPLC: tR 11.59 min (method A),
11.35 (method B), purity 95%. 1H NMR (DMSO-d6): δ 2.35 (s, 3H,
CH3), 2.88 (d, 3H, J = 4.8 Hz, CH3), 6.73 (dt, 1H, J = 9.2, 3.0 Hz, Ph-
H), 7.42 (d, 1H, J = 8.8 Hz, Ph-H), 8.20 (q, 1H, J = 4.8 Hz, NH), 8.69
(s, 1H, Py-H), 9.28 (s, 1H, OH), 10.11 (s, 1H, NH). 13C NMR
(DMSO-d6): δ 19.93, 31.26, 92.80, 115.46, 118.53, 123.43, 130.59,
154.22, 155.62, 159.59, 161.44, 163.83, 170.44. HR-MS (ESI+): m/z
[M + H]+ calcd for C16H15N6OS, 339.1028, found, 339.1089.
4-(4-Methyl-2-(methylamino)thiazol-5-yl)-2-((3-(morpho-
line-4-carbonyl)phenyl)amino)pyrimidine-5-carbonitrile (6). 6
was obtained from 3-(dimethylamino)-2-(4-methyl-2-(methylamino)-
thiazole-5-carbonyl)acrylonitrile and 1-(3-(morpholine-4-carbonyl)-
phenyl)guanidine. Yellow solid (26% yield); mp 131−132 °C. Anal.
RP-HPLC: tR min 12.87 (method A), 12.98 (method B), purity 98%.
1H NMR (DMSO-d6): δ 2.43 (s, 3H, CH3), 2.89 (d, 3H, J = 4.8 Hz,
CH3), 3.61 (br s, 8H, 4 × CH2), 7.10 (dt, 1H, J = 7.6, 1.2 Hz, Ph-H),
7.41 (t, 1H, J = 8.0 Hz, Ph-H), 7.72−7.80 (m, 1H, Ph-H), 7.85 (s, 1H,
Ph-H), 8.28 (q, 1H, J = 4.8 Hz, NH), 8.81 (s, 1H, Py-H), 10.37 (s, 1H,
NH). 13C NMR (DMSO-d6): δ 19.95, 31.34, 42.59, 48.14, 66.58,
94.44, 114.17, 118.17, 119.30, 121.82, 122.01, 129.23, 136.33, 139.50,
156.00, 159.36, 161.49, 164.07, 169.34, 170.70. HR-MS (ESI+): m/z
[M + H]+ calcd for C16H15N6OS, 436.1556, found, 436.1616.
N-Methyl-5-(2-((4-methyl-3-(morpholinosulfonyl)phenyl)-
amino)pyrimidin-4-yl)-4-phenylthiazol-2-amine (7). 7 was ob-
tained from tert-butyl (5-(3-(dimethylamino)acryloyl)-4-phenylthia-
zol-2-yl)(methyl)carbamate and 1-(4-methyl-3-(morpholinosulfonyl)-
phenyl)guanidine. Yellow solid (38% yield); mp 98−99 °C. Anal. RP-
HPLC: tR 11.34 min (method A), 11.78 (method B), purity 99%.
1H
NMR (DMSO-d6): δ 2.91 (d, 3H, J = 4.8 Hz, CH3), 3.07 (apparent t,
4H, J = 4.8 Hz, 2 × CH2), 3.64 (apparent t, 4H, J = 4.8 Hz, 2 × CH2),
6.27 (d, 1H, J = 5.2 Hz, Py-H), 7.36 (d, 1H, J = 8.8 Hz, Ph-H), 7.41−
7.60 (m, 5H, 5 × Ph-H), 7.97 (dd, 1H, J = 8.0, 2.0 Hz, Ph-H), 8.10 (d,
1H, J = 5.2 Hz, Py-H), 8.20 (q, 1H, J = 4.8 Hz, NH), 8.26 (d, 1H, J =
2.4 Hz, Ph-H), 9.78 (s, 1H, NH). 13C NMR (DMSO-d6): δ 20.16,
31.45, 45.82, 66.07, 107.61, 119.48, 119.68, 123.30, 129.10, 129.33,
129.38, 129.61, 133.50, 135.13, 136.51, 139.41, 154.53, 157.41, 159.34,
159.77, 170.44. HR-MS (ESI+): m/z [M + H]+ calcd for
C25H27N6O3S2, 523.1586, found, 523.1571.
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